RxDoctor Payments Data

Mario Ceja, MD

Family Medicine · Calexico, CANPI 1891753315

Payments from drug & device makers

$1,083in general payments, 2019–2025

Across 58 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$237
  • AstraZeneca$210
  • AbbVie$108
  • Amgen$103
  • Bayer$58
  • Merck$40
  • plus $328 from 14 others

What the payments were for

  • Food & beverage$1,083100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,083 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$728,734
Medicare patients
528
Services billed
11,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide189$191,515
EliquisApixaban127$142,021
JardianceEmpagliflozin115$122,399
EntrestoSacubitril/Valsartan86$96,279
RybelsusSemaglutide63$92,555
TrulicityDulaglutide75$91,872
LinzessLinaclotide85$76,222
FarxigaDapagliflozin Propanediol71$73,505
ProliaDenosumab44$71,252
MounjaroTirzepatide52$52,787
XareltoRivaroxaban36$52,473
TradjentaLinagliptin61$43,952
JanuviaSitagliptin Phosphate31$32,113
CreonLipase/Protease/Amylase18$27,267
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog50$20,998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$24$284,070252 claims
Lilly USA, LLCTrulicity, Mounjaro$237$144,659127 claims
PfizerEliquis$37$142,021127 claims
AbbVieLinzess, Creon$108$103,489103 claims
AstraZenecaFarxiga, Symbicort$210$81,729106 claims
AmgenProlia$103$71,25244 claims
Johnson & JohnsonXarelto$19$52,47336 claims
MerckJanuvia, Dulera$40$36,41442 claims
Astellas Pharma US IncMyrbetriq$16$16,85824 claims
GSKBreo Ellipta$22$8,83224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Calexico

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →